Optimizing Backfilling Strategies for Phase I Oncology Studies

Discover Ergomed’s latest whitepaper on backfilling strategies for Phase I oncology studies, offering an in-depth look at innovative dosing solutions for targeted therapies.

 
Learn how to optimize dose selection and response monitoring to ensure effective, timely progression to Recommended Phase 2 Dose (RP2D).
 
Essential for biotech and pharma companies aiming to streamline oncology drug development, this guide covers best practices for dose expansion, patient safety, and study efficiency.

"*" indicates required fields

Please enter your details to get access to the resource

By submitting this form, you consent to your personal data submitted in the form being processed in alignment with our Online Privacy and Cookies policy. Your personal data will be processed to facilitate your request and may be used for sending you additional marketing and business development-related information about Ergomed, its affiliates, and our services. You can withdraw your consent anytime by messaging marketing@ergomedgroup.com, and we will promptly remove your data from our records. For more information about how we will process your personal data and your rights, please see our Online Privacy and Cookies policy.
This field is for validation purposes and should be left unchanged.